Cargando…
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154535/ https://www.ncbi.nlm.nih.gov/pubmed/32130741 http://dx.doi.org/10.1002/pros.23967 |
_version_ | 1783521840522592256 |
---|---|
author | Shore, Neal D. Antonarakis, Emmanuel S. Cookson, Michael S. Crawford, E. David Morgans, Alicia K. Albala, David M. Hafron, Jason Harris, Richard G. Saltzstein, Daniel Brown, Gordon A. Henderson, Jonathan Lowentritt, Benjamin Spier, Jeffrey M. Concepcion, Raoul |
author_facet | Shore, Neal D. Antonarakis, Emmanuel S. Cookson, Michael S. Crawford, E. David Morgans, Alicia K. Albala, David M. Hafron, Jason Harris, Richard G. Saltzstein, Daniel Brown, Gordon A. Henderson, Jonathan Lowentritt, Benjamin Spier, Jeffrey M. Concepcion, Raoul |
author_sort | Shore, Neal D. |
collection | PubMed |
description | BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk‐benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. METHODS: A 14‐member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. RESULTS: This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting. CONCLUSION: The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate‐sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge. |
format | Online Article Text |
id | pubmed-7154535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71545352020-04-14 Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines Shore, Neal D. Antonarakis, Emmanuel S. Cookson, Michael S. Crawford, E. David Morgans, Alicia K. Albala, David M. Hafron, Jason Harris, Richard G. Saltzstein, Daniel Brown, Gordon A. Henderson, Jonathan Lowentritt, Benjamin Spier, Jeffrey M. Concepcion, Raoul Prostate Review Articles BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk‐benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. METHODS: A 14‐member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. RESULTS: This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting. CONCLUSION: The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate‐sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge. John Wiley and Sons Inc. 2020-03-04 2020-05-01 /pmc/articles/PMC7154535/ /pubmed/32130741 http://dx.doi.org/10.1002/pros.23967 Text en © 2020 The Authors. The Prostate published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Shore, Neal D. Antonarakis, Emmanuel S. Cookson, Michael S. Crawford, E. David Morgans, Alicia K. Albala, David M. Hafron, Jason Harris, Richard G. Saltzstein, Daniel Brown, Gordon A. Henderson, Jonathan Lowentritt, Benjamin Spier, Jeffrey M. Concepcion, Raoul Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title | Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title_full | Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title_fullStr | Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title_full_unstemmed | Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title_short | Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines |
title_sort | optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154535/ https://www.ncbi.nlm.nih.gov/pubmed/32130741 http://dx.doi.org/10.1002/pros.23967 |
work_keys_str_mv | AT shoreneald optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT antonarakisemmanuels optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT cooksonmichaels optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT crawfordedavid optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT morgansaliciak optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT albaladavidm optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT hafronjason optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT harrisrichardg optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT saltzsteindaniel optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT browngordona optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT hendersonjonathan optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT lowentrittbenjamin optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT spierjeffreym optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines AT concepcionraoul optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines |